Permanent hypogonadism after traumatic brain injury: a case report

Roberto Vita, Salvatore Benvenga


We report here a case of male post-traumatic hypogonadism, whose clinical manifestations occurred three years after a traumatic brain injury (TBI). The selective pituitary deficit was proven to be irreversible by discontinuing for six months testosterone replacement. The present case confirms that gonadotrophs failure is not uncommon after a TBI. Therefore, regular pituitary function monitoring after a TBI, especially if associated with loss of consciousness, is important for the early detection of hypopituitarism.


hypogonadism; traumatic brain injury; pituitary

Full Text:



1. Bhasin, S., Cunningham, G.R., Hayes, F.J., Matsumoto, A.M., Snyder, P.J., Swerdloff, R.S., Montori, V.M.; Task Force, Endocrine Society. (2010). Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab, 95(6), 2536-2559. doi: 10.1210/jc.2009-2354

2. Tanriverdi, F., Schneider, H.J., Aimaretti, G., Masel, B.E., Casanueva F.F., Kelestimur, F. (2015). Pituitary dysfunction after traumatic brain injury: a clinical and pathophysiological approach. Endocr Rev, 36(3), 305-342. doi: 10.1210/er.2014-1065

3. Benvenga, S., Bonardelli, M., Trimarchi, F., Degli Uberti, E.C. (2005) Ipopituitarismo e trauma cranico. L’Endocrinologo 6(3), 115-120.

4. Benvenga, S., Campenni, A., Ruggeri, R.M., Trimarchi, F. (2000). Clinical review 113: Hypopituitarism secondary to head trauma. J Clin Endocrinol Metab, 85(4), 1353–1361. doi: 10.1210/jcem.85.4.6506

5. Benvenga, S., Lo Giudice, F., Campenni, A., Longo, M., Trimarchi, F. (1997). Post-traumatic selective hypogonadotropic hypogonadism. J Endocrinol Invest, 20(11), 675-680. doi: 10.1007/BF03348031

6. Abraham, C., Cho, J.H. (2009). Inflammatory bowel disease. N Engl J Med, 361(21), 2066-2078. doi: 10.1056/NEJMra0804647

7. Tigas, S., Tsatsoulis, A. (2012). Endocrine and metabolic manifestations in inflammatory bowel disease. Ann Gastroenterol, 25(1), 37-44.

8. Abali, R., Tasdemir, N., Yuksel, M.A., Guzel, S., Oznur, M., Nalbantoglu, B., Tasdemir, U.G. (2013). Protective effect of infliximab on ischemia/reperfusion injury in a rat ovary model: biochemical and histopathologic evaluation. Eur J Obstet Gynecol Reprod Biol, 171(2), 353-357. doi:10.1016/j.ejogrb.2013.09.037

9. Said, T.M., Agarwal, A., Falcone, T., Sharma, R.K., Bedaiwy, M.A., Li, L. (2005). Infliximab may reverse the toxic effects induced by tumor necrosis factor alpha in human spermatozoa: an in vitro model. Fertil Steril 83(6), 1665-1673. doi: 10.1016/j.fertnstert.2004.11.068

DeBoer, M.D., Thayu, M., Griffin, L.M., Baldassano, R.N., Denson, L.A., Zemel, B.S., Denburg, M.R., Agard, H.E., Herskovitz, R., Long, J., Leonard, M.B. (2016). Anti-Tumor Necrosis Factor α Therapy in Adolescents with Crohn's Disease. J Pediatr 171, 146-152.e1-2. doi: 10.1016/j.jpeds.2016.01.003



  • There are currently no refbacks.

Copyright (c) 2018 Roberto Vita, Salvatore Benvenga

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.